{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:55:03Z","timestamp":1793174103282,"version":"4.5.0"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10620-011-1611-4","type":"journal-article","created":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T13:08:54Z","timestamp":1297775334000},"page":"958-976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["Drug-Induced Autoimmune-Like Hepatitis"],"prefix":"10.1007","volume":"56","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"1611_CR1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213.","journal-title":"Hepatology"},{"key":"1611_CR2","doi-asserted-by":"crossref","unstructured":"Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2010 [Epub ahead of print].","DOI":"10.1007\/s10620-010-1501-1"},{"key":"1611_CR3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02093820","volume":"41","author":"A Czaja","year":"1996","unstructured":"Czaja A, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996;41:305\u2013314.","journal-title":"Dig Dis Sci"},{"key":"1611_CR4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","volume":"105","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824\u20131832.","journal-title":"Gastroenterology"},{"key":"1611_CR5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.1840040409","volume":"4","author":"AJ Czaja","year":"1984","unstructured":"Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622\u2013627.","journal-title":"Hepatology"},{"key":"1611_CR6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.1840030510","volume":"3","author":"JE Hegarty","year":"1983","unstructured":"Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685\u2013689.","journal-title":"Hepatology"},{"key":"1611_CR7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/jhep.2002.32485","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890\u2013897.","journal-title":"Hepatology"},{"key":"1611_CR8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","volume":"102","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005\u20131012.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u2013938.","journal-title":"J Hepatol"},{"key":"1611_CR10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/17474124.1.1.129","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007;1:129\u2013143.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1611_CR11","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","volume":"19","author":"VJ Desmet","year":"1994","unstructured":"Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513\u20131520.","journal-title":"Hepatology"},{"key":"1611_CR12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0168-8278(05)80279-X","volume":"18","author":"AJ Czaja","year":"1993","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993;18:342\u2013352.","journal-title":"J Hepatol"},{"key":"1611_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000171594","volume":"15","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis. 1997;15:125\u2013144.","journal-title":"Dig Dis"},{"key":"1611_CR14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/hep.510260229","volume":"26","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26:459\u2013466.","journal-title":"Hepatology"},{"key":"1611_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1386-6346(02)00274-7","volume":"25","author":"N Okano","year":"2003","unstructured":"Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263\u2013270.","journal-title":"Hepatol Res"},{"key":"1611_CR16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1542-3565(04)00246-0","volume":"2","author":"WR Kessler","year":"2004","unstructured":"Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625\u2013631.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1611_CR17","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0168-8278(94)80251-3","volume":"21","author":"GA Nikias","year":"1994","unstructured":"Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866\u2013871.","journal-title":"J Hepatol"},{"key":"1611_CR18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00000478-199506000-00010","volume":"19","author":"LJ Burgart","year":"1995","unstructured":"Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19:699\u2013708.","journal-title":"Am J Surg Pathol"},{"key":"1611_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","volume":"35","author":"J Kogan","year":"2002","unstructured":"Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002;35:75\u201381.","journal-title":"J Clin Gastroenterol"},{"key":"1611_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","volume":"42","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53\u201362.","journal-title":"Hepatology"},{"key":"1611_CR21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0025-6196(12)60515-1","volume":"66","author":"AJ Czaja","year":"1991","unstructured":"Czaja AJ, Taswell HF, Rakela J, Schimek CM. Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis. Mayo Clin Proc. 1991;66:572\u2013582.","journal-title":"Mayo Clin Proc"},{"key":"1611_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02063938","volume":"40","author":"AJ Czaja","year":"1995","unstructured":"Czaja AJ, Magrin S, Fabiano C, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci. 1995;40:33\u201340.","journal-title":"Dig Dis Sci"},{"key":"1611_CR23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jhep.2001.27562","volume":"34","author":"AJ Czaja","year":"2001","unstructured":"Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34:659\u2013665.","journal-title":"Hepatology"},{"key":"1611_CR24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1478-3231.2004.0924.x","volume":"24","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int. 2004;24:322\u2013329.","journal-title":"Liver Int"},{"key":"1611_CR25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0168-8278(98)80004-4","volume":"29","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29:198\u2013206.","journal-title":"J Hepatol"},{"key":"1611_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0168-8278(91)90864-8","volume":"13","author":"S Magrin","year":"1991","unstructured":"Magrin S, Craxi A, Fiorentino G, et al. Is autoimmune chronic active hepatitis a HCV-related disease? J Hepatol. 1991;13:56\u201360.","journal-title":"J Hepatol"},{"key":"1611_CR27","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bjornsson","year":"2010","unstructured":"Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040\u20132048.","journal-title":"Hepatology"},{"key":"1611_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u2013176.","journal-title":"Hepatology"},{"key":"1611_CR29","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","volume":"48","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48:1540\u20131548.","journal-title":"Hepatology"},{"key":"1611_CR30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","volume":"52","author":"RJ Fontana","year":"2010","unstructured":"Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730\u2013742.","journal-title":"Hepatology"},{"key":"1611_CR31","first-page":"627","volume-title":"Autoimmune Liver Diseases","author":"JH Lewis","year":"1998","unstructured":"Lewis JH, Zimmerman HJ. Drug-induced autoimmune liver disease. In: Krawitt EL, Wiesner RH, Nishioka K, eds. Autoimmune Liver Diseases. 2nd ed. Amsterdam: Elsevier; 1998:627\u2013649.","edition":"2"},{"key":"1611_CR32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1089-3261(02)00025-9","volume":"6","author":"ZX Liu","year":"2002","unstructured":"Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6:755\u2013774.","journal-title":"Clin Liver Dis"},{"key":"1611_CR33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","volume":"129","author":"RJ Andrade","year":"2005","unstructured":"Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512\u2013521.","journal-title":"Gastroenterology"},{"key":"1611_CR34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/hep.21095","volume":"43","author":"PB Watkins","year":"2006","unstructured":"Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43:618\u2013631.","journal-title":"Hepatology"},{"key":"1611_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1089-3261(05)70097-0","volume":"4","author":"HJ Zimmerman","year":"2000","unstructured":"Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4:73\u201396. (vi).","journal-title":"Clin Liver Dis"},{"key":"1611_CR36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.2008.058248","volume":"62","author":"R Ramachandran","year":"2009","unstructured":"Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62:481\u2013492.","journal-title":"J Clin Pathol"},{"key":"1611_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000282065","volume":"28","author":"HP Dienes","year":"2010","unstructured":"Dienes HP, Drebber U. Pathology of immune-mediated liver injury. Dig Dis. 2010;28:57\u201362.","journal-title":"Dig Dis"},{"key":"1611_CR38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","volume":"61","author":"Y Meier","year":"2005","unstructured":"Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005;61:135\u2013143.","journal-title":"Eur J Clin Pharmacol"},{"key":"1611_CR39","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","volume":"138","author":"N Chalasani","year":"2010","unstructured":"Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246\u20132259.","journal-title":"Gastroenterology"},{"key":"1611_CR40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","volume":"36","author":"C Sgro","year":"2002","unstructured":"Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451\u2013455.","journal-title":"Hepatology"},{"key":"1611_CR41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/00365528209182041","volume":"17","author":"M Dossing","year":"1982","unstructured":"Dossing M, Andreasen PB. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol. 1982;17:205\u2013211.","journal-title":"Scand J Gastroenterol"},{"key":"1611_CR42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","volume":"24","author":"MB De Valle","year":"2006","unstructured":"De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187\u20131195.","journal-title":"Aliment Pharmacol Ther"},{"key":"1611_CR43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.0954-6820.1967.tb10873.x","volume":"182","author":"M Bjorneboe","year":"1967","unstructured":"Bjorneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis. Acta Med Scand. 1967;182:491\u2013501.","journal-title":"Acta Med Scand"},{"key":"1611_CR44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archinte.1974.00320200029002","volume":"134","author":"RR Miller","year":"1974","unstructured":"Miller RR. Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med. 1974;134:219\u2013223.","journal-title":"Arch Intern Med"},{"key":"1611_CR45","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0025-7125(16)30638-1","volume":"73","author":"JH Lewis","year":"1989","unstructured":"Lewis JH, Zimmerman HJ. Drug-induced liver disease. Med Clin North Am. 1989;73:775\u2013792.","journal-title":"Med Clin North Am"},{"key":"1611_CR46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-2007-1007247","volume":"16","author":"R Williams","year":"1996","unstructured":"Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis. 1996;16:343\u2013348.","journal-title":"Semin Liver Dis"},{"key":"1611_CR47","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0168-8278(03)00405-7","volume":"39","author":"R Williams","year":"2003","unstructured":"Williams R. Changing clinical patterns in acute liver failure. J Hepatol. 2003;39:660\u2013661.","journal-title":"J Hepatol"},{"key":"1611_CR48","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","volume":"349","author":"WM Lee","year":"2003","unstructured":"Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474\u2013485.","journal-title":"N Engl J Med"},{"key":"1611_CR49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.meg.0000250581.77865.68","volume":"19","author":"SH Hussaini","year":"2007","unstructured":"Hussaini SH, O\u2019Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007;19:15\u201320.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1611_CR50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","volume":"58","author":"FJ de Abajo","year":"2004","unstructured":"de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58:71\u201380.","journal-title":"Br J Clin Pharmacol"},{"key":"1611_CR51","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","volume":"135","author":"N Chalasani","year":"2008","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924\u20131934, 1934:e1921\u2013e1924.","journal-title":"Gastroenterology"},{"key":"1611_CR52","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/ajg.2010.287","volume":"105","author":"H Devarbhavi","year":"2010","unstructured":"Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396\u20132404.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/17425251003601979","volume":"6","author":"DB Njoku","year":"2010","unstructured":"Njoku DB. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. Expert Opin Drug Metab Toxicol. 2010;6:519\u2013531.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1611_CR54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","volume":"33","author":"KM Boberg","year":"1998","unstructured":"Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99\u2013103.","journal-title":"Scand J Gastroenterol"},{"key":"1611_CR55","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","volume":"43","author":"M Werner","year":"2008","unstructured":"Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232\u20131240.","journal-title":"Scand J Gastroenterol"},{"key":"1611_CR56","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2010.02.008","volume":"8","author":"VK Agarwal","year":"2010","unstructured":"Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463\u2013470.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1611_CR57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01071970","volume":"18","author":"GB Goldstein","year":"1973","unstructured":"Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic hepatitis. Am J Dig Dis. 1973;18:177\u2013184.","journal-title":"Am J Dig Dis"},{"key":"1611_CR58","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0016-5085(77)80042-5","volume":"72","author":"WC Maddrey","year":"1977","unstructured":"Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology. 1977;72:1348\u20131353.","journal-title":"Gastroenterology"},{"key":"1611_CR59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2008-1040723","volume":"1","author":"LB Seeff","year":"1981","unstructured":"Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis. 1981;1:104\u2013115.","journal-title":"Semin Liver Dis"},{"key":"1611_CR60","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00917019","volume":"7","author":"Y Shoenfeld","year":"1987","unstructured":"Shoenfeld Y, Vilner Y, Reshef T, et al. Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16\/6 Id, 32\/15 Id) is induced by procainamide. J Clin Immunol. 1987;7:410\u2013419.","journal-title":"J Clin Immunol"},{"key":"1611_CR61","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0016-5085(91)90547-X","volume":"101","author":"MO Silva","year":"1991","unstructured":"Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology. 1991;101:840\u2013842.","journal-title":"Gastroenterology"},{"key":"1611_CR62","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/0016-5085(95)90139-6","volume":"108","author":"L Garcia-Buey","year":"1995","unstructured":"Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 1995;108:1770\u20131777.","journal-title":"Gastroenterology"},{"key":"1611_CR63","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372\u20138377.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1611_CR64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","volume":"37","author":"AM Di Giacomo","year":"2010","unstructured":"Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499\u2013507.","journal-title":"Semin Oncol"},{"key":"1611_CR65","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.3748\/wjg.14.5474","volume":"14","author":"A Takahashi","year":"2008","unstructured":"Takahashi A, Kanno Y, Takahashi Y, et al. Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report. World J Gastroenterol. 2008;14:5474\u20135477.","journal-title":"World J Gastroenterol"},{"key":"1611_CR66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0168-8278(87)80039-9","volume":"5","author":"G Babany","year":"1987","unstructured":"Babany G, Larrey D, Pessayre D, et al. Chronic active hepatitis caused by benzarone. J Hepatol. 1987;5:332\u2013335.","journal-title":"J Hepatol"},{"key":"1611_CR67","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/BF01316809","volume":"38","author":"LJ Scully","year":"1993","unstructured":"Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci. 1993;38:744\u2013751.","journal-title":"Dig Dis Sci"},{"key":"1611_CR68","first-page":"1048","volume":"18","author":"PH Bernard","year":"1994","unstructured":"Bernard PH, Lamouliatte H, Le Bail B, et al. Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate. Gastroenterol Clin Biol. 1994;18:1048\u20131049.","journal-title":"Gastroenterol Clin Biol"},{"key":"1611_CR69","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10620-009-0805-5","volume":"55","author":"P Martinez-Odriozola","year":"2010","unstructured":"Martinez-Odriozola P, Gutierrez-Macias A, Ibarmia-Lahuerta J, Munoz-Sanchez J. Meloxicam as a cause of drug-induced autoimmune hepatitis. Dig Dis Sci. 2010;55:1191\u20131192.","journal-title":"Dig Dis Sci"},{"key":"1611_CR70","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10620-006-9525-2","volume":"52","author":"JJ Lewis","year":"2007","unstructured":"Lewis JJ, Iezzoni JC, Berg CL. Methylphenidate-induced autoimmune hepatitis. Dig Dis Sci. 2007;52:594\u2013597.","journal-title":"Dig Dis Sci"},{"key":"1611_CR71","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0016-5085(86)90887-5","volume":"90","author":"E Poncin","year":"1986","unstructured":"Poncin E, Silvain C, Touchard G, Barbier J, Beauchant M. Papaverine-induced chronic liver disease. Gastroenterology. 1986;90:1051\u20131053.","journal-title":"Gastroenterology"},{"key":"1611_CR72","first-page":"2233","volume":"91","author":"MJ Sterling","year":"1996","unstructured":"Sterling MJ, Kane M, Grace ND. Pemoline-induced autoimmune hepatitis. Am J Gastroenterol. 1996;91:2233\u20132234.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archinte.1975.00330020123017","volume":"135","author":"MS Fedotin","year":"1975","unstructured":"Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch Intern Med. 1975;135:319\u2013321.","journal-title":"Arch Intern Med"},{"key":"1611_CR74","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00005176-198905000-00025","volume":"8","author":"G Maggiore","year":"1989","unstructured":"Maggiore G, Larizza D, Lorini R, et al. Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. J Pediatr Gastroenterol Nutr. 1989;8:547\u2013548.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1611_CR75","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1191\/0961203303lu313cr","volume":"12","author":"IW Graziadei","year":"2003","unstructured":"Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003;12:409\u2013412.","journal-title":"Lupus"},{"key":"1611_CR76","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00042737-200308000-00014","volume":"15","author":"N Pelli","year":"2003","unstructured":"Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15:921\u2013924.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1611_CR77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","volume":"21","author":"B Noel","year":"2007","unstructured":"Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21:17\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1611_CR78","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0029-1240010","volume":"29","author":"MW Russo","year":"2009","unstructured":"Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29:412\u2013422.","journal-title":"Semin Liver Dis"},{"key":"1611_CR79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00042737-200505000-00019","volume":"17","author":"LM Wolters","year":"2005","unstructured":"Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2005;17:589\u2013590.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1611_CR80","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1080\/003655201300192076","volume":"36","author":"H Hinrichsen","year":"2001","unstructured":"Hinrichsen H, Luttges J, Kloppel G, Folsch UR, Schmidt WE. Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol. 2001;36:780\u2013783.","journal-title":"Scand J Gastroenterol"},{"key":"1611_CR81","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1345\/aph.1H400","volume":"41","author":"AH Paredes","year":"2007","unstructured":"Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother. 2007;41:880\u2013884.","journal-title":"Ann Pharmacother"},{"key":"1611_CR82","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ncpgasthep1055","volume":"5","author":"C Abraham","year":"2008","unstructured":"Abraham C, Hart J, Locke SM, Baker AL. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol. 2008;5:172\u2013176.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"1611_CR83","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/COC.0b013e31802b4ef7","volume":"32","author":"S Aliberti","year":"2009","unstructured":"Aliberti S, Grignani G, Allione P, et al. An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. Am J Clin Oncol. 2009;32:640\u2013641.","journal-title":"Am J Clin Oncol"},{"key":"1611_CR84","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","volume":"64","author":"V Germano","year":"2005","unstructured":"Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519\u20131520.","journal-title":"Ann Rheum Dis"},{"key":"1611_CR85","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578\u2013581.","journal-title":"Clin Rheumatol"},{"key":"1611_CR86","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10067-009-1179-y","volume":"28","author":"KM Carlsen","year":"2009","unstructured":"Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009;28:1001\u20131003.","journal-title":"Clin Rheumatol"},{"key":"1611_CR87","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MCG.0b013e3181a745e7","volume":"44","author":"T Adar","year":"2010","unstructured":"Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44:e20\u2013e22.","journal-title":"J Clin Gastroenterol"},{"key":"1611_CR88","doi-asserted-by":"crossref","unstructured":"Efe C, Purnak T, Ozaslan E, Wahlin S. Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor alpha agents. Hepatology. 2010 [Epub ahead of print].","DOI":"10.1002\/hep.23834"},{"key":"1611_CR89","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/ajg.2010.5","volume":"105","author":"TL Fong","year":"2010","unstructured":"Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol. 2010;105:1561\u20131566.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR90","first-page":"703","volume":"92","author":"T Kamiyama","year":"1997","unstructured":"Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol. 1997;92:703\u2013704.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR91","doi-asserted-by":"crossref","unstructured":"Guzman G, Kallwitz ER, Wojewoda C, et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Report Med. 2009:918156.","DOI":"10.1155\/2009\/918156"},{"key":"1611_CR92","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1572-0241.2001.03827.x","volume":"96","author":"ML Borum","year":"2001","unstructured":"Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol. 2001;96:1654\u20131655.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR93","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.gme.0000142914.55849.6a","volume":"11","author":"SM Cohen","year":"2004","unstructured":"Cohen SM, O\u2019Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause. 2004;11:575\u2013577.","journal-title":"Menopause"},{"key":"1611_CR94","first-page":"959","volume":"17","author":"M Ben Yahia","year":"1993","unstructured":"Ben Yahia M, Mavier P, Metreau JM, et al. Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases. Gastroenterol Clin Biol. 1993;17:959\u2013962.","journal-title":"Gastroenterol Clin Biol"},{"key":"1611_CR95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-117-2-129","volume":"117","author":"D Larrey","year":"1992","unstructured":"Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med. 1992;117:129\u2013132.","journal-title":"Ann Intern Med"},{"key":"1611_CR96","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1021\/tx800409r","volume":"22","author":"KM Gilbert","year":"2009","unstructured":"Gilbert KM, Przybyla B, Pumford NR, et al. Delineating liver events in trichloroethylene-induced autoimmune hepatitis. Chem Res Toxicol. 2009;22:626\u2013632.","journal-title":"Chem Res Toxicol"},{"key":"1611_CR97","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJM197110072851501","volume":"285","author":"TB Reynolds","year":"1971","unstructured":"Reynolds TB, Peters RL, Yamada S. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. N Engl J Med. 1971;285:813\u2013820.","journal-title":"N Engl J Med"},{"key":"1611_CR98","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/tx00039a023","volume":"7","author":"S Lecoeur","year":"1994","unstructured":"Lecoeur S, Bonierbale E, Challine D, et al. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol. 1994;7:434\u2013442.","journal-title":"Chem Res Toxicol"},{"key":"1611_CR99","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0026-895X(25)08911-4","volume":"42","author":"M Bourdi","year":"1992","unstructured":"Bourdi M, Gautier JC, Mircheva J, et al. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Mol Pharmacol. 1992;42:280\u2013285.","journal-title":"Mol Pharmacol"},{"key":"1611_CR100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0026-895X(25)10602-0","volume":"45","author":"M Bourdi","year":"1994","unstructured":"Bourdi M, Tinel M, Beaune PH, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol. 1994;45:1287\u20131295.","journal-title":"Mol Pharmacol"},{"key":"1611_CR101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/cs0720263","volume":"72","author":"J Neuberger","year":"1987","unstructured":"Neuberger J, Kenna JG. Halothane hepatitis: a model of immune mediated drug hepatotoxicity. Clin Sci (Lond). 1987;72:263\u2013270.","journal-title":"Clin Sci (Lond)"},{"key":"1611_CR102","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1432-1033.1994.tb19082.x","volume":"223","author":"U Christen","year":"1994","unstructured":"Christen U, Quinn J, Yeaman SJ, et al. Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid. Eur J Biochem. 1994;223:1035\u20131047.","journal-title":"Eur J Biochem"},{"key":"1611_CR103","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1023\/A:1018817926394","volume":"42","author":"D Herzog","year":"1997","unstructured":"Herzog D, Hajoui O, Russo P, Alvarez F. Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci. 1997;42:1100\u20131103.","journal-title":"Dig Dis Sci"},{"key":"1611_CR104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00002018-200023040-00006","volume":"23","author":"RA Lawrenson","year":"2000","unstructured":"Lawrenson RA, Seaman HE, Sundstrom A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23:333\u2013349.","journal-title":"Drug Saf"},{"key":"1611_CR105","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1023\/A:1018836004279","volume":"43","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149\u20132155.","journal-title":"Dig Dis Sci"},{"key":"1611_CR106","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0049-0172(99)80004-3","volume":"28","author":"O Elkayam","year":"1999","unstructured":"Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum. 1999;28:392\u2013397.","journal-title":"Semin Arthritis Rheum"},{"key":"1611_CR107","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1309\/KV2J-VX6Q-L95V-VDE4","volume":"114","author":"NS Goldstein","year":"2000","unstructured":"Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol. 2000;114:591\u2013598.","journal-title":"Am J Clin Pathol"},{"key":"1611_CR108","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/MEG.0b013e3282f493c5","volume":"20","author":"TJ Ford","year":"2008","unstructured":"Ford TJ, Dillon JF. Minocycline hepatitis. Eur J Gastroenterol Hepatol. 2008;20:796\u2013799.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1611_CR109","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archpedi.152.11.1132","volume":"152","author":"JE Teitelbaum","year":"1998","unstructured":"Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med. 1998;152:1132\u20131136.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1611_CR110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2169\/internalmedicine.42.48","volume":"42","author":"M Abe","year":"2003","unstructured":"Abe M, Furukawa S, Takayama S, et al. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med. 2003;42:48\u201352.","journal-title":"Intern Med"},{"key":"1611_CR111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00008480-199910000-00014","volume":"11","author":"AH Eichenfield","year":"1999","unstructured":"Eichenfield AH. Minocycline and autoimmunity. Curr Opin Pediatr. 1999;11:447\u2013456.","journal-title":"Curr Opin Pediatr"},{"key":"1611_CR112","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/MCG.0b013e31818c8801","volume":"43","author":"J Ramakrishna","year":"2009","unstructured":"Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol. 2009;43:787\u2013790.","journal-title":"J Clin Gastroenterol"},{"key":"1611_CR113","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hep.1840080327","volume":"8","author":"BH Stricker","year":"1988","unstructured":"Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8:599\u2013606.","journal-title":"Hepatology"},{"key":"1611_CR114","first-page":"184","volume":"4","author":"G Amit","year":"2002","unstructured":"Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J. 2002;4:184\u2013186.","journal-title":"Isr Med Assoc J"},{"key":"1611_CR115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0002-9343(79)90086-X","volume":"67","author":"DE Hatoff","year":"1979","unstructured":"Hatoff DE, Cohen M, Schweigert BF, Talbert WM. Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. Am J Med. 1979;67:117\u2013121.","journal-title":"Am J Med"},{"key":"1611_CR116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.44.5.731","volume":"44","author":"PG Aithal","year":"1999","unstructured":"Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731\u2013735.","journal-title":"Gut"},{"key":"1611_CR117","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.21424","volume":"44","author":"RJ Andrade","year":"2006","unstructured":"Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581\u20131588.","journal-title":"Hepatology"},{"key":"1611_CR118","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0002-9343(76)90564-7","volume":"60","author":"JS Rodman","year":"1976","unstructured":"Rodman JS, Deutsch DJ, Gutman SI. Methyldopa hepatitis. A report of six cases and review of the literature. Am J Med. 1976;60:941\u2013948.","journal-title":"Am J Med"},{"key":"1611_CR119","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3109\/00365528109181814","volume":"16","author":"AJ Arranto","year":"1981","unstructured":"Arranto AJ, Sotaniemi EA. Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short- and long-term exposure. Scand J Gastroenterol. 1981;16:853\u2013863.","journal-title":"Scand J Gastroenterol"},{"key":"1611_CR120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/bmj.312.7024.169","volume":"312","author":"A Gough","year":"1996","unstructured":"Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312:169\u2013172.","journal-title":"BMJ"},{"key":"1611_CR121","first-page":"1206","volume":"90","author":"AJ Czaja","year":"1995","unstructured":"Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995;90:1206\u20131211.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR122","first-page":"561","volume":"55","author":"JC Homberg","year":"1984","unstructured":"Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol. 1984;55:561\u2013570.","journal-title":"Clin Exp Immunol"},{"key":"1611_CR123","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1073\/pnas.84.2.551","volume":"84","author":"P Beaune","year":"1987","unstructured":"Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA. 1987;84:551\u2013555.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1611_CR124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.1996.tb01652.x","volume":"60","author":"PH Beaune","year":"1996","unstructured":"Beaune PH, Lecoeur S, Bourdi M, et al. Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol Suppl. 1996;60:89\u201392.","journal-title":"Eur J Haematol Suppl"},{"key":"1611_CR125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0026-895X(25)09234-X","volume":"50","author":"S Lecoeur","year":"1996","unstructured":"Lecoeur S, Andre C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol. 1996;50:326\u2013333.","journal-title":"Mol Pharmacol"},{"key":"1611_CR126","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1172\/JCI114660","volume":"85","author":"M Bourdi","year":"1990","unstructured":"Bourdi M, Larrey D, Nataf J, et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest. 1990;85:1967\u20131973.","journal-title":"J Clin Invest"},{"key":"1611_CR127","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00008571-199706000-00002","volume":"7","author":"C Belloc","year":"1997","unstructured":"Belloc C, Gauffre A, Andre C, Beaune PH. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics. 1997;7:181\u2013186.","journal-title":"Pharmacogenetics"},{"key":"1611_CR128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","volume":"51","author":"JN Pande","year":"1996","unstructured":"Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51:132\u2013136.","journal-title":"Thorax"},{"key":"1611_CR129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2002-30105","volume":"22","author":"D Larrey","year":"2002","unstructured":"Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145\u2013155.","journal-title":"Semin Liver Dis"},{"key":"1611_CR130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","volume":"128","author":"FF Fountain","year":"2005","unstructured":"Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116\u2013123.","journal-title":"Chest"},{"key":"1611_CR131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","volume":"44","author":"MM Cotreau","year":"2005","unstructured":"Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"1611_CR132","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2008.10.021","volume":"50","author":"E Bjornsson","year":"2009","unstructured":"Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50:511\u2013517.","journal-title":"J Hepatol"},{"key":"1611_CR133","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","volume":"49","author":"MI Lucena","year":"2009","unstructured":"Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49:2001\u20132009.","journal-title":"Hepatology"},{"key":"1611_CR134","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cld.2007.06.003","volume":"11","author":"MA Shapiro","year":"2007","unstructured":"Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11:477\u2013505. (v).","journal-title":"Clin Liver Dis"},{"key":"1611_CR135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/tx980249i","volume":"12","author":"JP Uetrecht","year":"1999","unstructured":"Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the \u201cdanger hypothesis\u201d and innate immune system. Chem Res Toxicol. 1999;12:387\u2013395.","journal-title":"Chem Res Toxicol"},{"key":"1611_CR136","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.pharmtox.47.120505.105150","volume":"47","author":"J Uetrecht","year":"2007","unstructured":"Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513\u2013539.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1611_CR137","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","volume":"47","author":"C Lammert","year":"2008","unstructured":"Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003\u20132009.","journal-title":"Hepatology"},{"key":"1611_CR138","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bmj.299.6697.519-a","volume":"299","author":"K Otani","year":"1989","unstructured":"Otani K, Kaneko S, Tasaki H, Fukushima Y. Hepatic injury caused by mianserin. BMJ. 1989;299:519.","journal-title":"BMJ"},{"key":"1611_CR139","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.1.2.159","volume":"1","author":"JH Lewis","year":"2002","unstructured":"Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf. 2002;1:159\u2013172.","journal-title":"Expert Opin Drug Saf"},{"key":"1611_CR140","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2004.03.030","volume":"126","author":"MW Russo","year":"2004","unstructured":"Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 2004;126:1477\u20131480.","journal-title":"Gastroenterology"},{"key":"1611_CR141","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","volume":"62","author":"N Vuilleumier","year":"2006","unstructured":"Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62:423\u2013429.","journal-title":"Eur J Clin Pharmacol"},{"key":"1611_CR142","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","volume":"132","author":"AK Daly","year":"2007","unstructured":"Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132:272\u2013281.","journal-title":"Gastroenterology"},{"key":"1611_CR143","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/clpt.1991.3","volume":"49","author":"MJ Rieder","year":"1991","unstructured":"Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 1991;49:13\u201317.","journal-title":"Clin Pharmacol Ther"},{"key":"1611_CR144","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","volume":"37","author":"YS Huang","year":"2003","unstructured":"Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924\u2013930.","journal-title":"Hepatology"},{"key":"1611_CR145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2007.02.009","volume":"47","author":"YS Huang","year":"2007","unstructured":"Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007;47:128\u2013134.","journal-title":"J Hepatol"},{"key":"1611_CR146","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.22370","volume":"48","author":"MI Lucena","year":"2008","unstructured":"Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008;48:588\u2013596.","journal-title":"Hepatology"},{"key":"1611_CR147","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/hep.23668","volume":"52","author":"MI Lucena","year":"2010","unstructured":"Lucena MI, Garcia-Martin E, Andrade RJ, et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010;52:303\u2013312.","journal-title":"Hepatology"},{"key":"1611_CR148","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.20205","volume":"39","author":"GP Aithal","year":"2004","unstructured":"Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430\u20131440.","journal-title":"Hepatology"},{"key":"1611_CR149","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/toxsci\/kfl180","volume":"97","author":"MM Ong","year":"2007","unstructured":"Ong MM, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci. 2007;97:205\u2013213.","journal-title":"Toxicol Sci"},{"key":"1611_CR150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/hep.23720","volume":"52","author":"S Russmann","year":"2010","unstructured":"Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology. 2010;52:748\u2013761.","journal-title":"Hepatology"},{"key":"1611_CR151","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/j.gastro.2008.01.038","volume":"134","author":"SS Strautnieks","year":"2008","unstructured":"Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134:1203\u20131214.","journal-title":"Gastroenterology"},{"key":"1611_CR152","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1053\/gast.1997.v112.pm9178696","volume":"112","author":"MD Strettell","year":"1997","unstructured":"Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028\u20132035.","journal-title":"Gastroenterology"},{"key":"1611_CR153","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cgh.2007.12.048","volume":"6","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1611_CR154","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","volume":"51","author":"C Lammert","year":"2010","unstructured":"Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615\u2013620.","journal-title":"Hepatology"},{"key":"1611_CR155","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","volume":"46","author":"C Benichou","year":"1993","unstructured":"Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs\u2014II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331\u20131336.","journal-title":"J Clin Epidemiol"},{"key":"1611_CR156","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323\u20131330.","journal-title":"J Clin Epidemiol"},{"key":"1611_CR157","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","volume":"26","author":"VA Maria","year":"1997","unstructured":"Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664\u2013669.","journal-title":"Hepatology"},{"key":"1611_CR158","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.22442","volume":"48","author":"J Rochon","year":"2008","unstructured":"Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008;48:1175\u20131183.","journal-title":"Hepatology"},{"key":"1611_CR159","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel\u2013Uclaf causality assessment method. Hepatology. 2010;51:2117\u20132126.","journal-title":"Hepatology"},{"key":"1611_CR160","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/0016-5085(81)90146-3","volume":"80","author":"DF Ransohoff","year":"1981","unstructured":"Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology. 1981;80:816\u2013819.","journal-title":"Gastroenterology"},{"key":"1611_CR161","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","volume":"105","author":"NH Shear","year":"1986","unstructured":"Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105:179\u2013184.","journal-title":"Ann Intern Med"},{"key":"1611_CR162","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9343(91)90216-K","volume":"91","author":"MA Gennis","year":"1991","unstructured":"Gennis MA, Vemuri R, Burns EA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med. 1991;91:631\u2013634.","journal-title":"Am J Med"},{"key":"1611_CR163","first-page":"177","volume":"3","author":"RM Victorino","year":"1985","unstructured":"Victorino RM, Maria VA. Modifications of the lymphocyte transformation test in a case of drug-induced cholestatic hepatitis. Diagn Immunol. 1985;3:177\u2013181.","journal-title":"Diagn Immunol"},{"key":"1611_CR164","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2249.1992.tb06426.x","volume":"87","author":"RM Victorino","year":"1992","unstructured":"Victorino RM, Maria VA, Pinto LA. Evidence for prostaglandin-producing suppressor cells in drug-induced liver injury and implications in the diagnosis of drug sensitization. Clin Exp Immunol. 1992;87:132\u2013137.","journal-title":"Clin Exp Immunol"},{"key":"1611_CR165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(05)80388-5","volume":"21","author":"VA Maria","year":"1994","unstructured":"Maria VA, Pinto L, Victorino RM. Lymphocyte reactivity to ex vivo drug antigens in drug-induced hepatitis. J Hepatol. 1994;21:151\u2013158.","journal-title":"J Hepatol"},{"key":"1611_CR166","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0168-8278(95)80270-3","volume":"22","author":"PA Berg","year":"1995","unstructured":"Berg PA, Becker EW. The lymphocyte transformation test\u2014a debated method for the evaluation of drug allergic hepatic injury. J Hepatol. 1995;22:115\u2013118.","journal-title":"J Hepatol"},{"key":"1611_CR167","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/jhep.2001.21083","volume":"33","author":"N Kaplowitz","year":"2001","unstructured":"Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33:308\u2013310.","journal-title":"Hepatology"},{"key":"1611_CR168","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","volume":"11","author":"C Benichou","year":"1990","unstructured":"Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272\u2013276.","journal-title":"J Hepatol"},{"key":"1611_CR169","first-page":"257","volume":"33","author":"C Benichou","year":"1991","unstructured":"Benichou C, Solal Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol. 1991;33:257\u2013262.","journal-title":"Nouv Rev Fr Hematol"},{"key":"1611_CR170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u2013245.","journal-title":"Clin Pharmacol Ther"},{"key":"1611_CR171","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","volume":"27","author":"M Garcia-Cortes","year":"2008","unstructured":"Garcia-Cortes M, Lucena MI, Pachkoria K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780\u2013789.","journal-title":"Aliment Pharmacol Ther"},{"key":"1611_CR172","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0168-8278(00)80127-0","volume":"33","author":"GP Aithal","year":"2000","unstructured":"Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol. 2000;33:949\u2013952.","journal-title":"J Hepatol"},{"key":"1611_CR173","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2001.20645","volume":"33","author":"MI Lucena","year":"2001","unstructured":"Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123\u2013130.","journal-title":"Hepatology"},{"key":"1611_CR174","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1386-6346(03)00232-8","volume":"27","author":"H Takikawa","year":"2003","unstructured":"Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27:192\u2013195.","journal-title":"Hepatol Res"},{"key":"1611_CR175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2007.03355.x","volume":"26","author":"E Bjornsson","year":"2007","unstructured":"Bjornsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:79\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"1611_CR176","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0016-5085(80)90866-5","volume":"78","author":"AJ Czaja","year":"1980","unstructured":"Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology. 1980;78:518\u2013523.","journal-title":"Gastroenterology"},{"key":"1611_CR177","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/14737159.4.2.189","volume":"4","author":"JC Lindon","year":"2004","unstructured":"Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn. 2004;4:189\u2013199.","journal-title":"Expert Rev Mol Diagn"},{"key":"1611_CR178","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.taap.2005.05.008","volume":"207","author":"S Ruepp","year":"2005","unstructured":"Ruepp S, Boess F, Suter L, et al. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol Appl Pharmacol. 2005;207:161\u2013170.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1611_CR179","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/CVI.13.2.258-265.2006","volume":"13","author":"DB Njoku","year":"2006","unstructured":"Njoku DB, Mellerson JL, Talor MV, et al. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin Vaccine Immunol. 2006;13:258\u2013265.","journal-title":"Clin Vaccine Immunol"},{"key":"1611_CR180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474124.1.1.113","volume":"1","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113\u2013128.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1611_CR181","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-8278(97)82329-X","volume":"26","author":"MA Robin","year":"1997","unstructured":"Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol. 1997;26:23\u201330.","journal-title":"J Hepatol"},{"key":"1611_CR182","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/tx700186p","volume":"21","author":"J Uetrecht","year":"2008","unstructured":"Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol. 2008;21:84\u201392.","journal-title":"Chem Res Toxicol"},{"key":"1611_CR183","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrd1720","volume":"4","author":"DC Liebler","year":"2005","unstructured":"Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov. 2005;4:410\u2013420.","journal-title":"Nat Rev Drug Discov"},{"key":"1611_CR184","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF03189993","volume":"23","author":"PM Dansette","year":"1998","unstructured":"Dansette PM, Bonierbale E, Minoletti C, et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet. 1998;23:443\u2013451.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1611_CR185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/egh.10.42","volume":"4","author":"AJ Czaja","year":"2010","unstructured":"Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2010;4:429\u2013443.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1611_CR186","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","volume":"6","author":"RA Wilke","year":"2007","unstructured":"Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6:904\u2013916.","journal-title":"Nat Rev Drug Discov"},{"key":"1611_CR187","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0029-1240009","volume":"29","author":"AK Daly","year":"2009","unstructured":"Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis. 2009;29:400\u2013411.","journal-title":"Semin Liver Dis"},{"key":"1611_CR188","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","volume":"41","author":"MS Longhi","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31\u201337.","journal-title":"J Hepatol"},{"key":"1611_CR189","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","volume":"25","author":"MS Longhi","year":"2005","unstructured":"Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4\u00a0+\u00a0CD25\u00a0+\u00a0regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63\u201371.","journal-title":"J Autoimmun"},{"key":"1611_CR190","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","volume":"176","author":"MS Longhi","year":"2006","unstructured":"Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4\u00a0+\u00a0CD25\u00a0+\u00a0regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484\u20134491.","journal-title":"J Immunol"},{"key":"1611_CR191","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991\u20131045.","journal-title":"Annu Rev Immunol"},{"key":"1611_CR192","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2174\/092986709788803097","volume":"16","author":"S Russmann","year":"2009","unstructured":"Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16:3041\u20133053.","journal-title":"Curr Med Chem"},{"key":"1611_CR193","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.20492","volume":"40","author":"JP Luyendyk","year":"2004","unstructured":"Luyendyk JP, Maddox JF, Green CD, Ganey PE, Roth RA. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology. 2004;40:1342\u20131351.","journal-title":"Hepatology"},{"key":"1611_CR194","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","volume":"4","author":"N Kaplowitz","year":"2005","unstructured":"Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489\u2013499.","journal-title":"Nat Rev Drug Discov"},{"key":"1611_CR195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2008-1040435","volume":"11","author":"IR Cohen","year":"1991","unstructured":"Cohen IR, Lohse AW. Physiology and pathophysiology of autoimmunity. Semin Liver Dis. 1991;11:183\u2013186.","journal-title":"Semin Liver Dis"},{"key":"1611_CR196","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0167-5699(00)01735-7","volume":"21","author":"DI Godfrey","year":"2000","unstructured":"Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21:573\u2013583.","journal-title":"Immunol Today"},{"key":"1611_CR197","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1478-3231.2010.02262.x","volume":"30","author":"Z Wu","year":"2010","unstructured":"Wu Z, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int. 2010;30:782\u2013794.","journal-title":"Liver Int"},{"key":"1611_CR198","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/hep.1840130415","volume":"13","author":"PT Donaldson","year":"1991","unstructured":"Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13:701\u2013706.","journal-title":"Hepatology"},{"key":"1611_CR199","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/hep.510300412","volume":"30","author":"S Cookson","year":"1999","unstructured":"Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851\u2013856.","journal-title":"Hepatology"},{"key":"1611_CR200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.510310110","volume":"31","author":"K Agarwal","year":"2000","unstructured":"Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31:49\u201353.","journal-title":"Hepatology"},{"key":"1611_CR201","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1572-0241.2005.41053.x","volume":"100","author":"A Hiraide","year":"2005","unstructured":"Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322\u20131329.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-0039.2006.00794.x","volume":"69","author":"K Agarwal","year":"2007","unstructured":"Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227\u2013235.","journal-title":"Tissue Antigens"},{"key":"1611_CR203","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3748\/wjg.v11.i18.2768","volume":"11","author":"LY Fan","year":"2005","unstructured":"Fan LY, Tu XQ, Zhu Y, et al. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol. 2005;11:2768\u20132772.","journal-title":"World J Gastroenterol"},{"key":"1611_CR204","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/j.1478-3231.2009.02028.x","volume":"29","author":"MW Milks","year":"2009","unstructured":"Milks MW, Cripps JG, Lin H, et al. The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis. Liver Int. 2009;29:1307\u20131315.","journal-title":"Liver Int"},{"key":"1611_CR205","doi-asserted-by":"crossref","first-page":"G525","DOI":"10.1152\/ajpgi.00286.2002","volume":"284","author":"C Schramm","year":"2003","unstructured":"Schramm C, Protschka M, Kohler HH, et al. Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2003;284:G525\u2013G535.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1611_CR206","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/jhep.2002.30084","volume":"35","author":"A Vogel","year":"2002","unstructured":"Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126\u2013131.","journal-title":"Hepatology"},{"key":"1611_CR207","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1440-1746.2005.03532.x","volume":"20","author":"L Fan","year":"2005","unstructured":"Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005;20:249\u2013255.","journal-title":"J Gastroenterol Hepatol"},{"key":"1611_CR208","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/egh.09.15","volume":"3","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269\u2013291.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1611_CR209","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","volume":"7","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319\u2013333.","journal-title":"Expert Opin Drug Saf"},{"key":"1611_CR210","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","volume":"29","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816\u2013823.","journal-title":"Liver Int"},{"key":"1611_CR211","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","volume":"51","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161\u2013167.","journal-title":"J Hepatol"},{"key":"1611_CR212","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","volume":"95","author":"AJ Czaja","year":"1988","unstructured":"Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448\u2013453.","journal-title":"Gastroenterology"},{"key":"1611_CR213","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","volume":"34","author":"S Kanzler","year":"2001","unstructured":"Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. 2001;34:354\u2013355.","journal-title":"J Hepatol"},{"key":"1611_CR214","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2001-13708","volume":"39","author":"S Kanzler","year":"2001","unstructured":"Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339\u2013341, 344\u2013348.","journal-title":"Z Gastroenterol"},{"key":"1611_CR215","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","volume":"63","author":"RD Soloway","year":"1972","unstructured":"Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820\u2013833.","journal-title":"Gastroenterology"},{"key":"1611_CR216","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0016-5085(81)90126-8","volume":"80","author":"AJ Czaja","year":"1981","unstructured":"Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80:687\u2013692.","journal-title":"Gastroenterology"},{"key":"1611_CR217","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","volume":"42","author":"S Luth","year":"2008","unstructured":"Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42:926\u2013930.","journal-title":"J Clin Gastroenterol"},{"key":"1611_CR218","first-page":"891","volume":"87","author":"LA Paiva","year":"1992","unstructured":"Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol. 1992;87:891\u2013893.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR219","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/toxsci\/kfi013","volume":"83","author":"LM Aleksunes","year":"2005","unstructured":"Aleksunes LM, Slitt AM, Cherrington NJ, et al. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci. 2005;83:44\u201352.","journal-title":"Toxicol Sci"},{"key":"1611_CR220","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple R. Hy\u2019s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15:241\u2013243.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1611_CR221","first-page":"S48","volume":"23","author":"J Venulet","year":"1985","unstructured":"Venulet J. Critical reflection on the collection and evaluation of adverse drug reaction data. Int J Clin Pharmacol Ther Toxicol. 1985;23:S48\u2013S53.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"1611_CR222","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1345\/aph.1D202","volume":"37","author":"WN Kelly","year":"2003","unstructured":"Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother. 2003;37:1774\u20131778.","journal-title":"Ann Pharmacother"},{"key":"1611_CR223","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1258\/0004563054890105","volume":"42","author":"C van Heyningen","year":"2005","unstructured":"van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem. 2005;42:402\u2013404.","journal-title":"Ann Clin Biochem"},{"key":"1611_CR224","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0009-2797(98)00081-7","volume":"116","author":"E Eliasson","year":"1998","unstructured":"Eliasson E, Gardner I, Hume-Smith H, et al. Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Chem Biol Interact. 1998;116:123\u2013141.","journal-title":"Chem Biol Interact"},{"key":"1611_CR225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000198597","volume":"22","author":"D Pessayre","year":"1981","unstructured":"Pessayre D, Degos F, Feldmann G, et al. Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin. Digestion.. 1981;22:66\u201372.","journal-title":"Digestion."},{"key":"1611_CR226","first-page":"769","volume":"13","author":"EA Pariente","year":"1989","unstructured":"Pariente EA, Hamoud A, Goldfain D, et al. Hepatitis caused by clometacin (Duperan). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis? Gastroenterol Clin Biol. 1989;13:769\u2013774.","journal-title":"Gastroenterol Clin Biol"},{"key":"1611_CR227","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archinte.1983.00350030206040","volume":"143","author":"O Shalev","year":"1983","unstructured":"Shalev O, Mosseri M, Ariel I, Stalnikowicz R. Methyldopa-induced immune hemolytic anemia and chronic active hepatitis. Arch Intern Med. 1983;143:592\u2013593.","journal-title":"Arch Intern Med"},{"key":"1611_CR228","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1001\/jama.1990.03450200068033","volume":"264","author":"SM Helfgott","year":"1990","unstructured":"Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. JAMA. 1990;264:2660\u20132662.","journal-title":"JAMA"},{"key":"1611_CR229","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00004836-199807000-00016","volume":"27","author":"G Bhat","year":"1998","unstructured":"Bhat G, Jordan J Jr, Sokalski S, et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27:74\u201375.","journal-title":"J Clin Gastroenterol"},{"key":"1611_CR230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2230.2008.03088.x","volume":"34","author":"DA Fairhurst","year":"2009","unstructured":"Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol. 2009;34:421\u2013422.","journal-title":"Clin Exp Dermatol"},{"key":"1611_CR231","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ibd.20293","volume":"14","author":"M Marques","year":"2008","unstructured":"Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723\u2013725.","journal-title":"Inflamm Bowel Dis"},{"key":"1611_CR232","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","volume":"187","author":"G Ozorio","year":"2007","unstructured":"Ozorio G, McGarity B, Bak H, et al. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524\u2013526.","journal-title":"Med J Aust"},{"key":"1611_CR233","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-92-1-14","volume":"92","author":"JR Sharp","year":"1980","unstructured":"Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 1980;92:14\u201319.","journal-title":"Ann Intern Med"},{"key":"1611_CR234","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0016-5085(19)32568-5","volume":"69","author":"M Black","year":"1975","unstructured":"Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975;69:289\u2013302.","journal-title":"Gastroenterology"},{"key":"1611_CR235","first-page":"1436","volume":"91","author":"A Nadir","year":"1996","unstructured":"Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol. 1996;91:1436\u20131438.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR236","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","volume":"96","author":"C Schramm","year":"2001","unstructured":"Schramm C, Kanzler S, zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001;96:1587\u20131591.","journal-title":"Am J Gastroenterol"},{"key":"1611_CR237","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","volume":"45","author":"T Al-Chalabi","year":"2006","unstructured":"Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45:575\u2013583.","journal-title":"J Hepatol"},{"key":"1611_CR238","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","volume":"43","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532\u2013538.","journal-title":"Hepatology"},{"key":"1611_CR239","first-page":"303","volume":"57","author":"GL Davis","year":"1982","unstructured":"Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc. 1982;57:303\u2013309.","journal-title":"Mayo Clin Proc"},{"key":"1611_CR240","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/BF01296447","volume":"31","author":"RP Kenny","year":"1986","unstructured":"Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci. 1986;31:705\u2013711.","journal-title":"Dig Dis Sci"},{"key":"1611_CR241","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","volume":"110","author":"SK Roberts","year":"1996","unstructured":"Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848\u2013857.","journal-title":"Gastroenterology"},{"key":"1611_CR242","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646\u2013652.","journal-title":"J Hepatol"},{"key":"1611_CR243","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/0016-5085(84)90186-0","volume":"87","author":"GL Davis","year":"1984","unstructured":"Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1984;87:1222\u20131227.","journal-title":"Gastroenterology"},{"key":"1611_CR244","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.20235","volume":"39","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology. 2004;39:1631\u20131638.","journal-title":"Hepatology"},{"key":"1611_CR245","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","volume":"46","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138\u20131145.","journal-title":"Hepatology"},{"key":"1611_CR246","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","volume":"27","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007;27:507\u2013515.","journal-title":"Liver Int"},{"key":"1611_CR247","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1572-0241.2002.05921.x","volume":"97","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051\u20132057.","journal-title":"Am J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-011-1611-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1611-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1611-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T11:40:02Z","timestamp":1740915602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-011-1611-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":247,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s10620-011-1611-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]},"assertion":[{"value":"10 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}